Gelonghui, November 9 | According to the Southwest Securities Research Report, the third quarter results of Shanghai Pharmaceutical (601607.SH) highlighted resilience, and the innovation pipeline has entered a harvest period, maintaining a “buy” rating. As of the end of 2023Q3, 3 new drug pipelines have submitted pre-NDAs or marketing applications. In the first three quarters of 2023, 3 new products were added to the company's new drug pipeline, 2 of which were innovative drugs. In October 2023, Shanghai Pharmaceutical Cloud Health completed Series C financing of 500 million yuan. This round C round of financing is jointly led by the Shanghai Comprehensive Reform Fund and ICBC Investment. The Shanghai Biomedical Fund continues to support it. It is expected that the path of independent development and listing will be fully launched in the future.